All In Biotech

NDA 215179 · Shilpa

Pemetrexed

Pemetrexed Disodium · Intravenous

Last checked: Nov 20, 2026Latest source record: Nov 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 22, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,474

328 Phase 3, 251 recruiting

FAERS reports

26,175

25,665 serious, 4,553 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 8, 2025.

1. INDICATIONS AND USAGE PEMRYDI RTU ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use: PEMRYDI RTU is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 ) 1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) PEMRYDI RTU ® is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. as a single agent for the treatment of patients with...

Mechanism: Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 22, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
3 products under this application
  • PEMETREXED · PEMETREXED DISODIUM EQ 1GM/100ML BASE (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • PEMETREXED · PEMETREXED DISODIUM EQ 100MG/10ML BASE (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • PEMETREXED · PEMETREXED DISODIUM EQ 500MG/50ML BASE (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pemetrexed Disodium" as an intervention, any sponsor and status, largest first.

All 1,474 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression2,103
  • anaemia1,501
  • nausea1,248
  • off label use1,239
  • diarrhoea1,220
  • neutropenia1,207
  • disease progression1,191
  • pancytopenia1,130
  • thrombocytopenia1,086
  • drug ineffective1,027
  • vomiting947
  • death943

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200461
200550
200628
200799
2008136
2009310
2010532
2011572
2012438
2013273
2014321
2015315
2016530
2017629
20181,047
20191,407
20201,528
20212,005
20222,510
20232,947
20243,811
20253,625
20263,001

Recalls

2 FDA enforcement reports for this application.

  • Jul 29, 2026 · Class II · Ongoing

    Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials

  • Jul 29, 2026 · Class II · Ongoing

    Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pemetrexed (Pemetrexed)

2024 spending

$29K

Beneficiaries

11

43 claims

Per beneficiary

$2,604

$201.14 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$28,649

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,004 on PubMed

Sponsor: Shilpa

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.